EP0503583A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Composition for sustained release of erythropoietin
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1992-03-11
•
Granted: —
•
Expires: 2012-03-11
Abstract
Abstract A composition which comprises erythropoietin and hyaluronic acid shows a sustained-release of the medicine in a living body.
Inventors
- 👤 Yasutaka Igari
- 👤 Minoru Yamada
- 👤 Yasuaki Ogawa
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-23 10:25
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1816; A61K47/00; A61K47/30; A61K47/36; A61K47/42
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
33 words
A sustained-release pharmaceutical composition, which comprises (1) erythropoietin, (2) an amount of hyaluronic acid or its nontoxic salt effective for the sustained-release of erythropoietin, and (3) a pharmaceutically acceptable carrier, diluent or excipient.
Claim 2
Dependent Claim
33 words
A composition in accordance with claim 1, which further comprises a water-soluble protein which has no practical pharmacological effect and is capable of being introduced into a body fluid of a warm-blooded animal.
Claim 3
Dependent Claim
12 words
A composition in accordance with claim 1, which is an injectable preparation.
Claim 4
Dependent Claim
12 words
A composition in accordance with claim 1, which is a lyophilized preparation.
Claim 5
Dependent Claim
12 words
A composition in accordance with claim 1, which is a liquid preparation.
Claim 6
Dependent Claim
31 words
A composition in accordance with claim 1, wherein said erythropoietin is an erythropoietin derivative or a physiologically active substance similar to erythropoietin in biological activity but different in amino acid composition.
Claim 7
Dependent Claim
28 words
A composition in accordance with claim 1, where said hyaluronic acid or its nontoxic salt thereof has a molecular weight of 5 x 10⁵ to 3 x 10⁶.
Claim 8
Dependent Claim
24 words
A composition in accordance with claim 1, wherein the weight ratio of erythropoietin to hyaluronic acid or its nontoxic salt is 0.0001:1 through 10:1.
Claim 9
Dependent Claim
15 words
A composition in accordance with claim 2, wherein the water-soluble protein is human serum albumin.
Claim 10
Dependent Claim
28 words
A composition in accordance with claim 2, wherein the weight ratio of the water-soluble protein to hyaluronic acid or its nontoxic salt is 0.001 : 1 through 100:1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.